Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition

Diabetologia

Volumn 60, Issue 2, 2017, Pages 215-225

  Vallon, Volker ^a,b,c   Thomson, Scott C ^a,c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

Body weight; Cardiovascular outcome; Chronic kidney disease; Diabetic nephropathy; EMPA REG OUTCOME trial; Glomerular hyperfiltration; Gluconeogenesis; Hypertension; Renal glucose reabsorption; Review; Sodium glucose cotransport

Indexed keywords

EMPAGLIFLOZIN; GLUCOSE; PHLORIZIN; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); DIABETIC PATIENT; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; GLUCOSE URINE LEVEL; HEART PROTECTION; HUMAN; HYPERGLYCEMIA; HYPERURICEMIA; HYPOGLYCEMIA; INSULIN RESISTANCE; KETOACIDOSIS; KIDNEY TUBULE ABSORPTION; META ANALYSIS (TOPIC); NATRIURESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; RENAL PROTECTION; REVIEW; ULTRAFILTRATION; UPREGULATION; WEIGHT REDUCTION; ANTAGONISTS AND INHIBITORS; DIABETES MELLITUS, TYPE 2; KIDNEY; METABOLISM; PHYSIOLOGY;

DIABETES MELLITUS, TYPE 2; GLUCOSE; HUMANS; HYPERGLYCEMIA; INSULIN RESISTANCE; KIDNEY; PHLORHIZIN; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84996486377     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-016-4157-3     Document Type: Review

References (87)

1. International Diabetes Federation (2013) www.idf.org/diabetesatlas. Accessed 15 Aug 2015
2. DeFronzo RA (2009) Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58:773–795
3. The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986
4. Gerstein HC, Miller ME, Byington RP et al (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545–2559
5. Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128
6. Wanner C, Inzucchi SE, Lachin JM et al (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375:323–334
7. Barfuss DW, Schafer JA (1981) Differences in active and passive glucose transport along the proximal nephron. Am J Physiol 241:F322–F332
8. Turner RJ, Moran A (1982) Heterogeneity of sodium-dependent D-glucose transport sites along the proximal tubule: evidence from vesicle studies. Am J Physiol 242:F406–F414
9. Wright EM, Loo DD, Hirayama BA (2011) Biology of human sodium glucose transporters. Physiol Rev 91:733–794
10. Santer R, Calado J (2010) Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. Clin J Am Soc Nephrol 5:133–141
11. Vrhovac I, Balen ED, Klessen D et al (2015) Localizations of Na-D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart. Pflugers Arch 467:1881–1898
12. Vallon V, Platt KA, Cunard R et al (2011) SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol 22:104–112
13. Sabolic I, Vrhovac I, Eror DB et al (2012) Expression of Na+-D-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences. Am J Physiol Cell Physiol 302:C1174–C1188
14. Rieg T, Masuda T, Gerasimova M et al (2014) Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. Am J Phys Renal Phys 306:F188–F193
15. Gorboulev V, Schurmann A, Vallon V et al (2012) Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes 61:187–196
16. Farber SJ, Berger EY, Earle DP (1951) Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose. J Clin Invest 30:125–129
17. Mogensen CE (1971) Maximum tubular reabsorption capacity for glucose and renal hemodynamcis during rapid hypertonic glucose infusion in normal and diabetic subjects. Scand J Clin Lab Invest 28:101–109
18. Vallon V, Rose M, Gerasimova M et al (2013) Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am J Physiol Renal Physiol 304:F156–F167
19. Vallon V, Gerasimova M, Rose MA et al (2014) SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol 306:F194–F204
20. Vallon V (2011) The proximal tubule in the pathophysiology of the diabetic kidney. Am J Physiol Regul Integr Comp Physiol 300:R1009–R1022
21. Seyer-Hansen K (1987) Renal hypertrophy in experimental diabetes: some functional aspects. J Diabet Complications 1:7–10
22. Gembardt F, Bartaun C, Jarzebska N et al (2014) The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension. Am J Physiol Ren Physiol 307:F317–F325
23. Ehrenkranz JR, Lewis NG, Kahn CR, Roth J (2005) Phlorizin: a review. Diabetes Metab Res Rev 21:31–38
24. Hummel CS, Lu C, Loo DD, Hirayama BA, Voss AA, Wright EM (2011) Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2. Am J Physiol Cell Physiol 300:C14–C21
25. Song P, Onishi A, Koepsell H, Vallon V (2016) Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus. Expert Opin Ther Targets 20:1109–1125
26. Vallon V (2015) The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu Rev Med 66:255–270
27. Bonner C, Kerr-Conte J, Gmyr V et al (2015) Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med 21:512–517
28. Washburn WN, Poucher SM (2013) Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus. Expert Opin Investig Drugs 22:463–486
29. Abdul-Ghani MA, DeFronzo RA (2014) Lowering plasma glucose concentration by inhibiting renal sodium-glucose co-transport. J Intern Med 276:352–363
30. Hasan FM, Alsahli M, Gerich JE (2014) SGLT2 inhibitors in the treatment of type 2 diabetes. Diabetes Res Clin Pract 104:297–322
31. Monami M, Nardini C, Mannucci E (2014) Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 16:457–466
32. Ferrannini E, Muscelli E, Frascerra S et al (2014) Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 124:499–508
33. Cherney DZ, Perkins BA, Soleymanlou N et al (2014) Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129:587–597
34. Jurczak MJ, Lee HY, Birkenfeld AL et al (2011) SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. Diabetes 60:890–898
35. Hansen HH, Jelsing J, Hansen CF et al (2014) The sodium glucose cotransporter type 2 inhibitor empagliflozin preserves beta-cell mass and restores glucose homeostasis in the male zucker diabetic fatty rat. J Pharmacol Exp Ther 350:657–664
36. Macdonald FR, Peel JE, Jones HB et al (2010) The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats. Diabetes Obes Metab 12:1004–1012
37. Merovci A, Solis-Herrera C, Daniele G et al (2014) Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 124:509–514
38. Komoroski B, Vachharajani N, Boulton D et al (2009) Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 85:520–526
39. Heise T, Seewaldt-Becker E, Macha S et al (2013) Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks’ treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes Metab 15:613–621
40. Sha S, Devineni D, Ghosh A et al (2011) Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 13:669–672
41. Bolinder J, Ljunggren O, Kullberg J et al (2012) Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 97:1020–1031
42. Geerlings S, Fonseca V, Castro-Diaz D, List J, Parikh S (2014) Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria. Diabetes Res Clin Pract 103:373–381
43. Guthrie RM (2013) Sodium-glucose co-transporter 2 inhibitors and the potential for cardiovascular risk reduction in patients with type 2 diabetes mellitus. Postgrad Med 125:21–32
44. Basile JN (2013) The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM). J Diabetes Complicat 27:280–286
45. Nagata T, Fukuzawa T, Takeda M et al (2013) Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice. Br J Pharmacol 170:519–531
46. Terami N, Ogawa D, Tachibana H et al (2014) Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PLoS One 9:e100777
47. Gangadharan KM, Gross S, Mudaliar H et al (2014) Inhibition of kidney proximal tubular glucose reabsorption does not prevent against diabetic nephropathy in type 1 diabetic eNOS knockout mice. PLoS One 9:e108994
48. Kojima N, Williams JM, Takahashi T, Miyata N, Roman RJ (2013) Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats. J Pharmacol Exp Ther 345:464–472
49. Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T (2005) Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 28:164–176
50. American Diabetes Association (2014) Standards of Medical Care in Diabetes - 2014. Diabetes Care 37:S14–S80
51. Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB (2014) Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens 8:262–275
52. Oliva RV, Bakris GL (2014) Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens 8:330–339
53. Foote C, Perkovic V, Neal B (2012) Effects of SGLT2 inhibitors on cardiovascular outcomes. Diab Vasc Dis Res 9:117–123
54. Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J (2013) Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 15:853–862
55. Bolinder J, Ljunggren O, Johansson L et al (2014) Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab 16:159–169
56. Cefalu WT, Leiter LA, Yoon KH et al (2013) Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 382:941–950
57. Yokono M, Takasu T, Hayashizaki Y et al (2014) SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats. Eur J Pharmacol 727:66–74
58. Suzuki M, Takeda M, Kito A et al (2014) Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models. Nutr Diabetes 4, e125
59. Kanbay M, Jensen T, Solak Y et al (2016) Uric acid in metabolic syndrome: from an innocent bystander to a central player. Eur J Intern Med 29:3–8
60. Lytvyn Y, Skrtic M, Yang GK, Yip PM, Perkins BA, Cherney DZ (2015) Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. Am J Physiol Renal Physiol 308:F77–F83
61. Chino Y, Samukawa Y, Sakai S et al (2014) SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm Drug Dispos 35:391–404
62. Magee GM, Bilous RW, Cardwell CR, Hunter SJ, Kee F, Fogarty DG (2009) Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis. Diabetologia 52:691–697
63. Layton AT, Vallon V, Edwards A (2016) Predicted consequences of diabetes and SGLT inhibition on transport and oxygen consumption along a rat nephron. Am J Physiol Ren Physiol 310:F1269–F1283
64. Vallon V, Thomson SC (2012) Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney. Annu Rev Physiol 74:351–375
65. Vallon V, Richter K, Blantz RC, Thomson S, Osswald H (1999) Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption. J Am Soc Nephrol 10:2569–2576
66. Thomson SC, Rieg T, Miracle C et al (2012) Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am J Physiol Regul Integr Comp Physiol 302:R75–R83
67. Heerspink HJ, Desai M, Jardine M, Balis D, Meininger G, Perkovic V (2016) Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol. doi:10.1681/ASN.2016030278
68. Yale JF, Bakris G, Cariou B et al (2013) Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 15:463–473
69. Barnett AH, Mithal A, Manassie J et al (2014) Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2:369–384
70. Holtkamp FA, de Zeeuw D, Thomas MC et al (2011) An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int 80:282–287
71. Neill O, Fasching A, Pihl L, Patinha D, Franzen S, Palm F (2015) Acute SGLT inhibition normalizes oxygen tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats. Am J Physiol Renal Physiol 309:F227–F234
72. Chang YK, Choi H, Jeong JY et al (2016) Dapagliflozin, SGLT2 inhibitor, attenuates renal ischemia-reperfusion injury. PLoS One 11:e0158810
73. Rosenberger C, Mandriota S, Jurgensen JS et al (2002) Expression of hypoxia-inducible factor-1alpha and -2alpha in hypoxic and ischemic rat kidneys. J Am Soc Nephrol 13:1721–1732
74. Ash SR, Cuppage FE (1970) Shift toward anaerobic glycolysis in the regenerating rat kidney. Am J Pathol 60:385–402
75. Lan R, Geng H, Singha PK et al (2016) Mitochondrial pathology and glycolytic shift during proximal tubule atrophy after ischemic AKI. J Am Soc Nephrol 27:3356–3367
76. Farsijani NM, Liu Q, Kobayashi H et al (2016) Renal epithelium regulates erythropoiesis via HIF-dependent suppression of erythropoietin. J Clin Invest 126:1425–1437
77. Koury ST, Bondurant MC, Koury MJ (1988) Localization of erythropoietin synthesizing cells in murine kidneys by in situ hybridization. Blood 71:524–527
78. Obara N, Suzuki N, Kim K, Nagasawa T, Imagawa S, Yamamoto M (2008) Repression via the GATA box is essential for tissue-specific erythropoietin gene expression. Blood 111:5223–5232
79. Pessoa TD, Campos LC, Carraro-Lacroix L, Girardi AC, Malnic G (2014) functional role of glucose metabolism, osmotic stress, and sodium-glucose cotransporter isoform-mediated transport on Na+/H+ exchanger isoform 3 activity in the renal proximal tubule. J Am Soc Nephrol 25:2028–2039
80. Coady MJ, El TA, Santer R et al (2016) MAP17 Is a necessary activator of renal Na+/glucose cotransporter SGLT2. J Am Soc Nephrol. doi:10.1681/ASN.2015111282
81. Fu Y, Gerasimova M, Mayoux E, Masuda T, Vallon V (2014) SGLT2 inhibitor empagliflozin increases renal NHE3 phosphorylation in diabetic Akita mice: possible implications for the prevention of glomerular hyperfiltration. Diabetes 63(supplement 1):A132
82. Gerich JE (2010) Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med 27:136–142
83. Food and Drug Administration (2015) www.fda.gov/Drugs/DrugSafety/ucm446845.htm. Accessed 10 Aug 2015
84. Mudaliar S, Alloju S, Henry RR (2016) Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME Study? A unifying hypothesis. Diabetes Care 39:1115–1122
85. Newman JC, Verdin E (2014) beta-hydroxybutyrate: much more than a metabolite. Diabetes Res Clin Pract 106:173–181
86. Ferrannini E, Mark M, Mayoux E (2016) CV Protection in the EMPA-REG OUTCOME Trial: a “thrifty substrate” hypothesis. Diabetes Care 39:1108–1114
87. Inzucchi SE, Zinman B, Wanner C et al (2015) SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res 12:90–100